For complex diseases, most drugs are highly ineffective, and the success rate of drug
discovery is in constant decline. While low quality, reproducibility issues, and translational …

Research in two fronts has enabled the development of therapies that provide significant
benefit to cancer patients. One area stems from a detailed knowledge of mutations that …

Somatic mutations have been extensively characterized in breast cancer, but the effects of
these genetic alterations on the proteomic landscape remain poorly understood. Here we …

Multi-omics approaches are novel frameworks that integrate multiple omics datasets
generated from the same patients to better understand the molecular and clinical features of …

The role of KRAS, when activated through canonical mutations, has been well established in
cancer. Here we explore a secondary means of KRAS activation in cancer: focal high-level …

Most cancers preserve functional retinoblastoma (Rb) and may, therefore, respond to
inhibition of D-cyclin-dependent Rb kinases, CDK4 and CDK6. To date, CDK4/6 inhibitors …

Activation of metastatic reprogramming is critical for tumour metastasis. However, more
detailed knowledge of the underlying mechanism is needed to enable targeted intervention …

The nuclear receptor–binding SET Domain (NSD) family of histone H3 lysine 36
methyltransferases is comprised of NSD1, NSD2 (MMSET/WHSC1), and NSD3 (WHSC1L1) …

Identification of driver genes contributes to the understanding of cancer etiology and is
imperative for the development of individualized therapies. Gene amplification is a major …

It has taken four decades of research to see the first major breakthrough for KRAS-driven
cancers. In particular, the last decade has seen a paradigm shift with the discovery of …